Treatment | Day of treatment or re-infestation | ||||||
---|---|---|---|---|---|---|---|
0 | 7 | 14 | 21 | 28 | 35 | ||
Placebo | Range | 17–42 | 20–38 | 15–40 | 19–40 | 27–40 | 25–41 |
A. mean | 28.6 | 30.5 | 30.9 | 31.9 | 34.4 | 32.1 | |
G. mean2 | 27.5a | 29.6a | 29.8a | 31.1a | 34.2a | 31.8a | |
Sarolaner | Range | 0–2 | 8–27 | 13–25 | 22–31 | 15–31 | 20–38 |
A. mean | 0.3 | 20.0 | 19.8 | 24.9 | 24.6 | 27.3 | |
Efficacy (%) | 99.1 | 34.4 | 36.0 | 22.0 | 28.4 | 15.2 | |
G. mean2 | 0.1b | 18.9b | 19.1b | 24.7a | 24.2b | 26.7a | |
Efficacy (%) | 99.5 | 36.1 | 35.9 | 20.5 | 29.2 | 15.9 | |
P-value vs. placebo | <0.0001 | 0.0142 | 0.0061 | 0.0754 | 0.0020 | 0.0715 | |
Afoxolaner | Range | 0–5 | 26–42 | 16–34 | 23–36 | 25–33 | 23–35 |
A. mean | 2.4 | 34.4 | 26.3 | 29.9 | 29.9 | 30.7 | |
Efficacy (%) | 91.5 | 0.0 | 14.9 | 6.3 | 13.1 | 4.4 | |
G. mean2 | 1.7c | 33.9a | 25.5a,b | 29.4a | 29.7a | 30.5a | |
Efficacy (%) | 93.8 | 0.0 | 14.6 | 5.5 | 13.0 | 4.1 | |
P-value vs. placebo | <0.0001 | 0.3251 | 0.3213 | 0.6858 | 0.0553 | 0.6435 | |
P-value vs. sarolaner | 0.0286 | 0.0015 | 0.0732 | 0.0770 | 0.0463 | 0.1679 |